Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2015-11-15 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Update on clinical trials of encapsulated pig islets 46 pages 3.2MB
Regulatory Filings
2015-11-15 English
Results of Annual General Meeting 3 pages 53.4KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement titled 'Results of Annual General Meeting held on 12 November 2015' for Living Cell Technologies Limited. It provides detailed voting results for resolutions presented at the AGM, including adoption of the Remuneration Report and re-election of a director. The content focuses on the official voting outcomes of shareholder resolutions at the AGM, referencing specific resolutions and poll results. There is no detailed financial data, management discussion, or full report content. The document is not a full Annual Report (10-K), nor a Management Report (MDA), nor a Remuneration Information report (DEF 14A). It is clearly the official declaration of voting results from the AGM, which matches the category 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length (6517 characters) supports it being a full announcement rather than a brief notice. Therefore, the correct classification is DVA with high confidence.
2015-11-12 English
Minister authorises Phase IIb Parkinson's study 3 pages 52.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 12 November 2015. It announces the authorization by the New Zealand Minister of Health to conduct a Phase IIb clinical study for Parkinson's disease treatment. The content focuses on the study protocol, patient recruitment plans, and clinical trial progress. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about a clinical trial authorization and study update, not a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about a clinical trial authorization, which aligns best with Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2015-11-11 English
CEO Presentation to Annual General Meeting 23 pages 1.2MB
AGM Information Classification · 100% confidence The document is a presentation by the CEO Dr. Ken Taylor given at the Annual General Meeting (AGM) on 12 November 2015. It contains forward-looking statements, milestones achieved in 2015, clinical trial results, regulatory input, financing updates, and strategic next steps. The content is typical of a presentation to shareholders at an AGM, focusing on business progress, clinical development, and future plans rather than detailed financial statements or regulatory filings. The presence of the CEO's name, the date, and the explicit mention of 'CEO Presentation to AGM' strongly indicates this is AGM presentation material. Therefore, the document fits the category of AGM Information (AGM-R).
2015-11-11 English
FY15 Annual Report - Rectification to Auditor's Report 4 pages 153.9KB
Audit Report / Information Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 11 November 2015. It states that the 2015 Annual Report included the 2014 Auditor's Report in error and appends the correct 2015 Auditor's Report. The document contains the full Independent Auditor's Report for the financial year ended 30 June 2015, including the auditor's opinion on the financial statements and the remuneration report. The presence of the full auditor's report with detailed audit opinion and references to the financial statements indicates this is a standalone audit report document, not the full annual report itself or just an announcement about it. The document length (10,416 characters) supports it being a substantive report rather than a brief announcement. Therefore, the document fits the category of Audit Report / Information (AR). FY 2015
2015-11-10 English
NTCELL - Parkinson's trial 42 week result 2 pages 51.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 27 October 2015. It reports clinical study results for a Parkinson's disease treatment, specifically the 42-week post-implant data from a Phase I/IIa clinical study. The content focuses on clinical trial progress and patient outcomes rather than financial data or regulatory filings. There is no indication that this is a full financial report, audit report, or earnings release. It is a company announcement about clinical trial progress and results, which does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or a report publication announcement since it contains substantive information about the clinical study results. The document is an announcement of clinical trial progress and results, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2015-10-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.